Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1x1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details.

About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia (FA). Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisors[email protected] (212) 915-2569

Company Contact:Michael CelanoChief Financial Officer[email protected](484) 414-2715

You May Also Be Interested In

• Iberia Cards Moves Beyond Point-in-Time Compliance with Synack
• STMicroelectronics and NUS launch Corporate Lab to power the future of Edge AI in Singapore
• NBPE: Neuberger Private Equity Partners Announces July Monthly NAV Update